Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 464.97% from the stock’s previous close.

ZNTL has been the subject of a number of other research reports. Wedbush reiterated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Wells Fargo & Company cut their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Finally, UBS Group decreased their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $1.77 on Monday. The firm has a market cap of $126.14 million, a PE ratio of -0.71 and a beta of 1.75. Zentalis Pharmaceuticals has a 12 month low of $1.61 and a 12 month high of $16.27. The firm has a 50 day simple moving average of $2.21 and a 200 day simple moving average of $2.95.

Insider Activity

In related news, Director Jan Skvarka acquired 60,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Ingmar Bruns bought 20,000 shares of the business’s stock in a transaction on Thursday, February 6th. The stock was bought at an average price of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ZNTL. Integral Health Asset Management LLC acquired a new position in Zentalis Pharmaceuticals in the 4th quarter worth about $3,182,000. Verition Fund Management LLC raised its position in Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after acquiring an additional 951,500 shares in the last quarter. Almitas Capital LLC lifted its stake in Zentalis Pharmaceuticals by 69.3% in the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock valued at $4,929,000 after acquiring an additional 665,968 shares during the last quarter. Boxer Capital Management LLC bought a new stake in Zentalis Pharmaceuticals in the fourth quarter worth approximately $1,364,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Zentalis Pharmaceuticals by 75.7% during the 4th quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company’s stock worth $2,605,000 after purchasing an additional 370,511 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.